Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ClouDr Group Limited (9955.HK)
Hangzhou, CN
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters and vital sign monitors, glucose testing strips, and both over-the-counter and prescription drugs. In addition to physical goods, ClouDr delivers software-as-a-service (SaaS) platforms tailored for healthcare facilities and pharmacies, while also offering digital marketing solutions to pharmaceutical companies. Furthermore, the company facilitates the management of chronic conditions through real-time online consultations, digital health monitoring, and remote prescription and ordering services. Established in 2014, ClouDr Group Limited maintains its primary corporate office in Hangzhou, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -8.70% | -10.00% | -18.18% | -43.24% | -37.00% | -40.00% | -91.42% | -97.77% | -97.77% | -97.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%-53.5% Q4'25: -46.4% (vs Q4'24)
-
EPS growth Medical - Distribution: +4.9%-70.8% Q4'25: +11.8% (vs Q4'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-23.1% Q4'25: -13.9% (vs Q4'24)
-
EBIT margin Medical - Distribution: +3.0%-35.7% Q4'25: -1.1% (vs Q4'24)
-
ROIC Medical - Distribution: +5.7%-177.5% Q4'25: -4.3% (vs Q4'24)
-
Share dilution Medical - Distribution: +0.0%+5.1% Q4'25: +6.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-0.58× Q4'25: 4.22× (vs Q4'24)
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
2.99B
est: 3.24B (-7.7%)
|
3.69B
est: 3.73B (-1.1%)
|
3.49B
est: 4.83B (-27.7%)
|
1.62B
est: 6.13B (-73.5%)
|
8.01B
8.01B – 8.01B
+30.8% YoY
|
| EBITDA |
-1.58B
est: -1.74B (+9.2%)
|
-208.37M
est: -1.49B (+86.0%)
|
-372.34M
est: -1.93B (+80.7%)
|
-495.62M
est: -2.45B (+79.8%)
|
-3.20B
-3.20B – -3.20B
-30.8% YoY
|
| EBIT |
-1.69B
est: -1.80B (+6.5%)
|
-316.54M
est: -1.60B (+80.2%)
|
-473.88M
est: -2.07B (+77.1%)
|
-579.76M
est: -2.63B (+77.9%)
|
-3.44B
-3.44B – -3.44B
-30.8% YoY
|
| Net Income |
-1.69B
est: -507.62M (-232.7%)
|
-323.07M
est: -285.98M (-13.0%)
|
-516.41M
est: -128.02M (-303.4%)
|
-924.15M
est: -88.39M (-945.5%)
|
69.57M
69.57M – 69.57M
+178.7% YoY
|
| SGA |
1.27B
est: 1.60B (-20.8%)
|
1.17B
est: 1.69B (-31.0%)
|
1.04B
est: 2.19B (-52.4%)
|
1.02B
est: 2.78B (-63.4%)
|
3.64B
3.64B – 3.64B
+30.8% YoY
|
| EPS |
-3.28
est: -0.87 (-275.0%)
|
-0.60
est: -0.47 (-27.9%)
|
-0.89
est: -0.21 (-324.0%)
|
-1.52
est: -0.14 (-948.7%)
|
0.11
0.11 – 0.11
+178.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P China ETF GXC | 0.00% | 5.3K | 0.59% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 28.2K | 0.39% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 13.2K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ming Kuang | Founder, Chairman & Chief Executive Officer | 7M | male |
| Yue Hu | Executive Director | 4M | female |
| Gang Li | Head of Technology Department | — | male |
| Lili Xu | Chief Financial Officer | — | female |
| Wai Sum Fung | Joint Company Secretary | — | female |
| Xiaohua Liu | Chief Scientist | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9955.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
